Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65892 | 1.00 | DPYD (0.62) | DPYDMAPTALDH1A1GAAATAD2 | |
| SCHEMBL14793573 | 0.91 | DPYD (0.66) | DPYDMAPTALDH1A1GAAATAD2 | |
| SCHEMBL6512588 | 0.83 | DPYD (0.59) | DPYDMAPTALDH1A1GAAATAD2 | |
| SCHEMBL933037 | 0.83 | DPYD (0.59) | DPYDMAPTALDH1A1GAAATAD2 | |
| SCHEMBL5559312 | 0.82 | ATAD2 (0.53) | DPYDMAPTALDH1A1GAAATAD2 | |
| SCHEMBL5559308 | 0.82 | ATAD2 (0.53) | DPYDMAPTALDH1A1GAAATAD2 | |
| SCHEMBL8966741 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1GAAATAD2 | |
| SCHEMBL8776005 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1GAAATAD2 | |
| SCHEMBL12903446 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1GAAATAD2 | |
| SCHEMBL190328 | 0.76 | DPYD (0.59) | DPYDMAPTALDH1A1GAAATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| US-10260071-B2 | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity | COLEY PHARMACEUTICAL GMBH (DE) | 2019-04-16 | — | — | US | claimed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-9677067-B2 | Compositions and methods for synthetic gene assembly | Twist Bioscience Corporation (US) | 2017-06-13 | — | — | US | claimed |
| US-20170159044-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation | 2017-06-08 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-20160348115-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | PFIZER INC. | 2016-12-01 | — | — | US | claimed |
| CN-106170553-A | Modified nucleic acid molecules and uses thereof | 现代治疗公司 | 2016-11-30 | — | — | CN | claimed |
| EP-0475992-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-03-25 | — | — | EP | claimed |
| EP-0464511-A2 | Process for the preparation of acyclic, substituted nucleosides and its intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-08 | — | — | EP | claimed |
| EP-0283065-B1 | COMBINATIONS OF FU AND BVU AS ANTI-ADENOCARCINOMA AGENTS | Stichting REGA V.Z.W. (BE) | 1991-05-29 | — | — | EP | claimed |
| US-4988678-A | Fluorouracil and tetrahydrofuryl-5-fluorouracil as an antitumor agent and bromovinyluracil and 5-(2-bromovinyl-2'-deoxyuridine | STICHTING REGA VZW (BE) | 1991-01-29 | — | — | US | claimed |
| WO-1990015064-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-13 | — | — | WO | claimed |
| EP-0391411-A2 | 3'-Substituted methyl nucleosides as antiviral agents | Bristol-Myers Squibb Company (US) | 1990-10-10 | — | — | EP | claimed |
| US-4894365-A | 5-FLUOROURACIL AND BROMOVINYLURACIL | STICHTING REGA VZW (BE) | 1990-01-16 | — | — | US | claimed |
| EP-0283065-A1 | Combinations of FU and BVU as anti-adenocarcinoma agents | Stichting REGA V.Z.W. (BE) | 1988-09-21 | — | — | EP | claimed |
| EP-0273169-A2 | Novel antiviral agents | SRI INTERNATIONAL (US) | 1988-07-06 | — | — | EP | claimed |
| WO-1984004748-A2 | NOVEL ANTIVIRAL AGENTS | — | 1984-12-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | DPYD 369/4885MAPT 3589/4885ALDH1A1 2324/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | DPYD 369/4885MAPT 3589/4885ALDH1A1 2324/4885 |
| US-10260071-B2 | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity | TLR9, TYMP, STING1 | DPYD 34/4885MAPT 4234/4885ALDH1A1 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.